pharmaphorum January 19, 2025
A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada’s Antibe Therapeutics, a developer of drugs for pain and inflammation that fell into receivership last year.
The transaction would see Antibe taken over by Taro Pharmaceutical – which merged with Sun Pharma unit last year – but is subject to approval by the Ontario Superior Court of Justice, according to a financial filing. The all-cash deal is expected to close by 7th March, but the value won’t be disclosed until after completion due to Canada’s receivership rules.
Antibe has been subject to a cease trade order under Ontario’s securities legislation since July 24, after failing to file audited financial statements for the year ending 31st...
Today's Sponsors
Today's Sponsor